步长制药：全资子公司撤回药品上市许可注册申请

Core Viewpoint - The company has decided to withdraw its drug registration application for "Empagliflozin Tablets" due to the need for further improvement of the submission materials, but this does not signify the termination of the project [1] Group 1 - The company's wholly-owned subsidiary, Shandong Danhong, received a termination notice from the National Medical Products Administration regarding the drug registration application for "Empagliflozin Tablets" [1] - The decision to withdraw the application was made after careful consideration and research [1] - The company plans to resubmit the drug registration application after completing the necessary research [1]